Inhibition of enterovirus 71 by adenosine analog NITD008

Journal of Virology

Volumn 88, Issue 20, 2014, Pages 11915-11923

  Deng, Cheng Lin ^a   Yeo, Huimin ^b   Ye, Han Qing ^a   Liu, Si Qing ^a   Shang, Bao Di ^a   Gong, Peng ^a   Alonso, Sylvie ^b   Shi, Pei Yong ^c   Zhang, Bo ^a  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c Novartis Institute for Tropical Diseases   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DERIVATIVE; NITD 008; RUPINTRIVIR; UNCLASSIFIED DRUG; ADENOSINE; ANTIVIRUS AGENT; NITD008;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CELL CULTURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DEATH; DRUG EFFICACY; DRUG POTENCY; ENTEROVIRUS 71; ENTEROVIRUS INFECTION; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; VIRUS INHIBITION; VIRUS LOAD; VIRUS MUTANT; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; ANIMAL; CHLOROCEBUS AETHIOPS; DRUG EFFECTS; ENTEROVIRUS; ENTEROVIRUS INFECTIONS; GENETICS; GROWTH, DEVELOPMENT AND AGING; MUTATION; PATHOPHYSIOLOGY; PHYSIOLOGY; VERO CELL LINE; VIRAL PLAQUE ASSAY; VIROLOGY;

ADENOSINE; ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; DRUG RESISTANCE, VIRAL; ENTEROVIRUS A, HUMAN; ENTEROVIRUS INFECTIONS; MICE; MUTATION; VERO CELLS; VIRAL LOAD; VIRAL PLAQUE ASSAY; VIRUS REPLICATION;

EID: 84907440604     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01207-14     Document Type: Article

References (44)

1. Mao Q, Wang Y, Yao X, Bian L, Wu X, Xu M, Liang Z. 2014. Coxsackievirus A16: epidemiology, diagnosis, and vaccine. Hum. Vaccin. Immunother. 10:360-367. http://dx.doi.org/10.4161/hv.27087.
2. Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H. 2009. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat. Med. 15:794-797. http://dx.doi.org/10.1038/nm.1961.
3. Schmidt NJ, Lennette EH, Ho HH. 1974. An apparently new enterovirus isolated from patients with disease of the central nervous system. J. Infect. Dis. 129:304-309. http://dx.doi.org/10.1093/infdis/129.3.304.
4. Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, Tan X, Wang L, Mao Q, Wu J, Hu Y, Ji T, Song L, Liang Q, Zhang B, Gao Q, Li J, Wang S, Hu Y, Gu S, Zhang J, Yao G, Gu J, Wang X, Zhou Y, Chen C, Zhang M, Cao M, Wang J, Wang H, Wang N. 2014. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N. Engl. J. Med. 370:818-828. http://dx.doi.org/10.1056/NEJMoa1304923.
5. Li JX, Mao QY, Liang ZL, Ji H, Zhu FC. 2014. Development of enterovirus 71 vaccines: from the lab bench to phase III clinical trials. Expert Rev. Vaccines 13:609-618. http://dx.doi.org/10.1586/14760584.2014.897617.
6. Paul AV, Rieder E, Kim DW, van Boom JH, Wimmer E. 2000. Identification of an RNA hairpin in poliovirus RNA that serves as the primary template in the in vitro uridylylation of VPg. J. Virol. 74:10359-10370. http://dx.doi.org/10.1128/JVI.74.22.10359-10370.2000.
7. De Palma AM, Thibaut HJ, van der Linden L, Lanke K, Heggermont W, Ireland S, Andrews R, Arimilli M, Al-Tel TH, De Clercq E, van Kuppeveld F, Neyts J. 2009. Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob. Agents Chemother. 53:1850-1857. http://dx.doi.org/10.1128/AAC.00934-08.
8. Thibaut HJ, De Palma AM, Neyts J. 2012. Combating enterovirus replication: state-of-the-art on antiviral research. Biochem. Pharmacol. 83:185-192. http://dx.doi.org/10.1016/j.bcp.2011.08.016.
9. Wu KX, Ng MM, Chu JJ. 2010. Developments towards antiviral therapies against enterovirus 71. Drug Discov. Today 15:1041-1051. http://dx.doi.org/10.1016/j.drudis.2010.10.008.
10. Kok CC, Phuektes P, Bek E, McMinn PC. 2012. Modification of the untranslated regions of human enterovirus 71 impairs growth in a cell-specific manner. J. Virol. 86:542-552. http://dx.doi.org/10.1128/JVI.00069-11.
11. Kuo RL, Shih SR. 2013. Strategies to develop antivirals against enterovirus 71. Virol. J. 10:28. http://dx.doi.org/10.1186/1743-422X-10-28.
12. Hayden FG, Andries K, Janssen PA. 1992. Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrob. Agents Chemother. 36:727-732. http://dx.doi.org/10.1128/AAC.36.4.727.
13. Barnard DL, Hubbard VD, Smee DF, Sidwell RW, Watson KG, Tucker SP, Reece PA. 2004. In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity. Antimicrob. Agents Chemother. 48: 1766-1772. http://dx.doi.org/10.1128/AAC.48.5.1766-1772.2004.
14. Shih SR, Tsai MC, Tseng SN, Won KF, Shia KS, Li WT, Chern JH, Chen GW, Lee CC, Lee YC, Peng KC, Chao YS. 2004. Mutation in enterovirus 71 capsid protein VP1 confers resistance to the inhibitory effects of pyridyl imidazolidinone. Antimicrob. Agents Chemother. 48:3523-3529. http: //dx.doi.org/10.1128/AAC.48.9.3523-3529.2004.
15. Matthews DA, Dragovich PS, Webber SE, Fuhrman SA, Patick AK, Zalman LS, Hendrickson TF, Love RA, Prins TJ, Marakovits JT, Zhou R, Tikhe J, Ford CE, Meador JW, Ferre RA, Brown EL, Binford SL, Brothers MA, DeLisle DM, Worland ST. 1999. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc. Natl. Acad. Sci. U. S. A. 96:11000-11007. http://dx.doi.org/10.1073/pnas.96.20.11000.
16. Lu G, Qi J, Chen Z, Xu X, Gao F, Lin D, Qian W, Liu H, Jiang H, Yan J, Gao GF. 2011. Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J. Virol. 85:10319-10331. http://dx.doi.org/10.1128/JVI.00787-11.
17. Kishimoto C, Crumpacker CS, Abelmann WH. 1988. Ribavirin treatment of murine coxsackievirus B3 myocarditis with analyses of lymphocyte subsets. J. Am. Coll. Cardiol. 12:1334-1341. http://dx.doi.org/10.1016/0735-1097(88)92618-6.
18. Goris N, De Palma A, Toussaint JF, Musch I, Neyts J, De Clercq K. 2007. 2'-C-methylcytidine as a potent and selective inhibitor of the replication of foot-and-mouth disease virus. Antiviral Res. 73:161-168. http: //dx.doi.org/10.1016/j.antiviral.2006.09.007.
19. Graci JD, Too K, Smidansky ED, Edathil JP, Barr EW, Harki DA, Galarraga JE, Bollinger JM, Jr, Peterson BR, Loakes D, Brown DM, Cameron CE. 2008. Lethal mutagenesis of picornaviruses with N-6-modified purine nucleoside analogues. Antimicrob. Agents Chemother. 52:971-979. http://dx.doi.org/10.1128/AAC.01056-07.
20. Khong WX, Yan B, Yeo H, Tan EL, Lee JJ, Ng JK, Chow VT, Alonso S. 2012. A non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing neurological manifestations in a novel mouse model of EV71 infection. J. Virol. 86:2121-2131. http://dx.doi.org/10.1128/JVI.06103-11.
21. Yin Z, Chen YL, Schul W, Wang QY, Gu F, Duraiswamy J, Kondreddi RR, Niyomrattanakit P, Lakshminarayana SB, Goh A, Xu HY, Liu W, Liu B, Lim JY, Ng CY, Qing M, Lim CC, Yip A, Wang G, Chan WL, Tan HP, Lin K, Zhang B, Zou G, Bernard KA, Garrett C, Beltz K, Dong M, Weaver M, He H, Pichota A, Dartois V, Keller TH, Shi PY. 2009. An adenosine nucleoside inhibitor of dengue virus. Proc. Natl. Acad. Sci. U. S. A. 106:20435-20439. http://dx.doi.org/10.1073/pnas.0907010106.
22. Shang B, Deng C, Ye H, Xu W, Yuan Z, Shi PY, Zhang B. 2013. Development and characterization of a stable eGFP enterovirus 71 for antiviral screening. Antiviral Res. 97:198-205. http://dx.doi.org/10.1016 /j.antiviral.2012.12.010.
23. Singh S, Poh CL, Chow VT. 2002. Complete sequence analyses of enterovirus 71 strains from fatal and non-fatal cases of the hand, foot and mouth disease outbreak in Singapore (2000). Microbiol. Immunol. 46: 801-808. http://dx.doi.org/10.1111/j.1348-0421.2002.tb02767.x.
24. Khong WX, Yan B, Yeo HM, Tan EL, Lee JJ, Ng JK, Chow VT, Alonso S. 2012. A non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing neurological manifestations in a novel mouse model of EV71 infection. J. Virol. 86:2121-2131. http://dx.doi.org/10.1128/JVI.06103-11.
25. Lin YJ, Chang YC, Hsiao NW, Hsieh JL, Wang CY, Kung SH, Tsai FJ, Lan YC, Lin CW. 2012. Fisetin and rutin as 3C protease inhibitors of enterovirus A71. J. Virol. Methods 182:93-98. http://dx.doi.org/10.1016/j.jviromet.2012.03.020.
26. Wang J, Fan T, Yao X, Wu Z, Guo L, Lei X, Wang M, Jin Q, Cui S. 2011. Crystal structures of enterovirus 71 3C protease complexed with rupintrivir reveal the roles of catalytically important residues. J. Virol. 85:10021-10030. http://dx.doi.org/10.1128/JVI.05107-11.
27. Leyssen P, Balzarini J, De Clercq E, Neyts J. 2005. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J. Virol. 79:1943-1947. http://dx.doi.org/10.1128/JVI.79.3.1943-1947.2005.
28. Crotty S, Cameron CE, Andino R. 2001. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. U. S. A. 98:6895-6900. http://dx.doi.org/10.1073/pnas.111085598.
29. Thomas E, Feld JJ, Li Q, Hu Z, Fried MW, Liang TJ. 2011. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 53:32-41. http://dx.doi.org/10.1002/hep.23985.
30. Thompson AA, Peersen OB. 2004. Structural basis for proteolysisdependent activation of the poliovirus RNA-dependent RNA polymerase. EMBO J. 23:3462-3471. http://dx.doi.org/10.1038/sj.emboj.7600357.
31. Pfeiffer JK, Kirkegaard K. 2003. A single mutation in poliovirus RNAdependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc. Natl. Acad. Sci. U. S. A. 100:7289-7294. http://dx.doi.org/10.1073/pnas.1232294100.
32. Sadeghipour S, Bek EJ, McMinn PC. 2013. Ribavirin-resistant mutants of human enterovirus 71 express a high replication fidelity phenotype during growth in cell culture. J. Virol. 87:1759-1769. http://dx.doi.org/10.1128/JVI.02139-12.
33. Gong P, Kortus MG, Nix JC, Davis RE, Peersen OB. 2013. Structures of coxsackievirus, rhinovirus, and poliovirus polymerase elongation complexes solved by engineering RNA mediated crystal contacts. PLoS One 8(5):e60272. http://dx.doi.org/10.1371/journal.pone.0060272.
34. Gong P, Peersen OB. 2010. Structural basis for active site closure by the poliovirus RNA-dependent RNA polymerase. Proc. Natl. Acad. Sci. U. S. A. 107:22505-22510. http://dx.doi.org/10.1073/pnas.1007626107.
35. Barton DJ, Morasco BJ, Eisner-Smerage L, Collis PS, Diamond SE, Hewlett MJ, Merchant MA, O'Donnell BJ, Flanegan JB. 1996. Poliovirus RNA polymerase mutation 3D-M394T results in a temperature-sensitive defect in RNA synthesis. Virology 217:459-469. http://dx.doi.org/10.1006/viro.1996.0140.
36. Harrison DN, Gazina EV, Purcell DF, Anderson DA, Petrou S. 2008. Amiloride derivatives inhibit coxsackievirus B3 RNA replication. J. Virol. 82:1465-1473. http://dx.doi.org/10.1128/JVI.01374-07.
37. Gazina EV, Smidansky ED, Holien JK, Harrison DN, Cromer BA, Arnold JJ, Parker MW, Cameron CE, Petrou S. 2011. Amiloride is a competitive inhibitor of coxsackievirus B3 RNA polymerase. J. Virol. 85: 10364-10374. http://dx.doi.org/10.1128/JVI.05022-11.
38. Giachetti C, Hwang SS, Semler BL. 1992. cis-Acting lesions targeted to the hydrophobic domain of a poliovirus membrane protein involved in RNA replication. J. Virol. 66:6045-6057.
39. Liu Y, Franco D, Paul AV, Wimmer E. 2007. Tyrosine 3 of poliovirus terminal peptide VPg(3B) has an essential function in RNA replication in the context of its precursor protein, 3AB. J. Virol. 81:5669-5684. http://dx.doi.org/10.1128/JVI.02350-06.
40. Paul AV, Cao X, Harris KS, Lama J, Wimmer E. 1994. Studies with poliovirus polymerase 3Dpol. Stimulation of poly(U) synthesis in vitro by purified poliovirus protein 3AB. J. Biol. Chem. 269:29173-29181.
41. Plotch SJ, Palant O. 1995. Poliovirus protein 3AB forms a complex with and stimulates the activity of the viral RNA polymerase, 3Dpol. J. Virol. 69:7169-7179.
42. Richards OC, Ehrenfeld E. 1998. Effects of poliovirus 3AB protein on 3D polymerase-catalyzed reaction. J. Biol. Chem. 273:12832-12840. http://dx.doi.org/10.1074/jbc.273.21.12832.
43. Hope DA, Diamond SE, Kirkegaard K. 1997. Genetic dissection of interaction between poliovirus 3D polymerase and viral protein 3AB. J. Virol. 71:9490-9498.
44. Simmons CP, Wolbers M, Nguyen MN, Whitehorn J, Shi PY, Young P, Petric R, Nguyen VV, Farrar J, Wills B. 2012. Therapeutics for dengue: recommendations for design and conduct of early-phase clinical trials. PLoS Negl. Trop. Dis. 6(9):e1752. http://dx.doi.org/10.1371/journal.pntd.0001752.